Biosino Bio-Technology and Science (HKSE:08247) WACC %:8.82% (As of Aug. 20, 2026) — 81% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:08247 Biosino Bio-Technology and Science Inc HKSE:08247
37 GF Score
Price HK$3.17
GF Value HK$0.44
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Biosino Bio-Technology and Science WACC %?

Biosino Bio-Technology and Science HKSE:08247 -2.62% 37 WACC % is 8.82% as of Aug. 20, 2026, which is 81% above its 10-year median of 4.87. GuruFocus rates HKSE:08247 with a GF Score™ of 37/100 and a GF Value™ of HK$0.44 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 216 Medical Diagnostics & Research companies, Biosino Bio-Technology and Science ranks better than 50.46% on this metric.

As of today (2026-08-20), Biosino Bio-Technology and Science's weighted average cost of capital is 8.82%%. Biosino Bio-Technology and Science's ROIC % is -15.58% (calculated using TTM income statement data). Biosino Bio-Technology and Science earns returns that do not match up to its cost of capital. It will destroy value as it grows.

For a comprehensive WACC calculation, please access the WACC Calculator.


Biosino Bio-Technology and Science  (HKSE:08247) WACC % Explanation

Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Biosino Bio-Technology and Science's weighted average cost of capital is 8.82%%. Biosino Bio-Technology and Science's ROIC % is -15.58% (calculated using TTM income statement data). Biosino Bio-Technology and Science earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.

2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.

3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.

4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.


Related Terms

Biosino Bio-Technology and Science WACC % Historical Data

* Premium members only.

The historical data trend for Biosino Bio-Technology and Science's WACC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biosino Bio-Technology and Science WACC % Chart

Biosino Bio-Technology and Science Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
WACC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.69 3.00 2.72 5.26 4.48

Biosino Bio-Technology and Science Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
WACC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.72 4.14 5.26 5.55 4.48

HKSE:08247 vs TMO, DHR, IDXX: WACC % Comparison

For the Diagnostics & Research subindustry, Biosino Bio-Technology and Science's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosino Bio-Technology and Science WACC % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biosino Bio-Technology and Science's WACC % distribution charts can be found below:

* The bar in red indicates where Biosino Bio-Technology and Science's WACC % falls into.


HKSE:08247
37GF Score
Biosino Bio-Technology and Science Inc HKSE:08247
WACC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biosino Bio-Technology and Science WACC % Calculation

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.

WACC=E/(E + D)*Cost of Equity+D/(E + D)*Cost of Debt*(1 - Tax Rate)

1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Biosino Bio-Technology and Science's market capitalization (E) is HK$457.998 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year semi-annual average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Dec. 2025, Biosino Bio-Technology and Science's latest one-year semi-annual average Book Value of Debt (D) is HK$166.2883 Mil.
a) weight of equity = E / (E + D) = 457.998 / (457.998 + 166.2883) = 0.7336
b) weight of debt = D / (E + D) = 166.2883 / (457.998 + 166.2883) = 0.2664

2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.69%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Biosino Bio-Technology and Science's beta is 0.9602.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.69% + 0.9602 * 6% = 10.4512%

3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year semi-annual average debt to get the simplified cost of debt.
As of Dec. 2025, Biosino Bio-Technology and Science's interest expense (positive number) was HK$7.469 Mil. Its total Book Value of Debt (D) is HK$166.2883 Mil.
Cost of Debt = 7.469 / 166.2883 = 4.4916%.

4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = -2.463 / -74.027 = 3.33%.

Biosino Bio-Technology and Science's Weighted Average Cost Of Capital (WACC) for Today is calculated as:

WACC=E / (E + D)*Cost of Equity+D / (E + D)*Cost of Debt*(1 - Tax Rate)
=0.7336*10.4512%+0.2664*4.4916%*(1 - 3.33%)
=8.82%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about WACC % →
What does a WACC % of 8.82% mean?
Biosino Bio-Technology and Science (HKSE:08247) has a WACC % of 8.82% as of Aug. 20, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Biosino Bio-Technology and Science and its competitors. This is 81% above median its historical median of 4.87. Over the past decade, Biosino Bio-Technology and Science's WACC % has ranged from 1.69 to 8.84. According to the industry distribution chart, Biosino Bio-Technology and Science ranks #107 out of 216 companies in the Medical Diagnostics & Research industry, placing it in the top 49.5%.
Is Biosino Bio-Technology and Science's WACC % too high?
Biosino Bio-Technology and Science's current WACC % of 8.82% is 81% above median its 10-year median of 4.87. Over the past 10 years, this metric has ranged from a low of 1.69 to a high of 8.84. The Medical Diagnostics & Research industry median WACC % is 8.95. Biosino Bio-Technology and Science's value of 8.82% is 1.4% below this industry median. Based on the distribution chart, Biosino Bio-Technology and Science ranks #107 out of 216 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Biosino Bio-Technology and Science has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biosino Bio-Technology and Science's WACC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Biosino Bio-Technology and Science ranks #107 out of 216 companies for WACC %. This puts Biosino Bio-Technology and Science in the upper half of its industry. The industry median WACC % is 8.95. Biosino Bio-Technology and Science's value of 8.82% is 1.4% below this benchmark. Historically, Biosino Bio-Technology and Science's own WACC % has ranged from 1.69 to 8.84 over the past decade. While the company's 10-year median is 4.87 vs. the industry median of 8.95, Biosino Bio-Technology and Science has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Medical Diagnostics & Research company?
The median WACC % among Medical Diagnostics & Research companies is 8.95, based on 216 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biosino Bio-Technology and Science's current WACC % of 8.82% is 1.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Biosino Bio-Technology and Science and its competitors. For the Medical Diagnostics & Research industry, the median WACC % is 8.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biosino Bio-Technology and Science's current WACC % is 8.82%, which is 81% above median its own 10-year median of 4.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosino Bio-Technology and Science stock overvalued right now?
Based on GuruFocus' analysis, Biosino Bio-Technology and Science (HKSE:08247) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.44, compared to a current price of HK$3.17 — trading 619.3% above its estimated fair value. The current WACC % is 8.82%, which is 81% above median its 10-year median of 4.87 and 1.4% below the Medical Diagnostics & Research industry median of 8.95. Biosino Bio-Technology and Science's overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Biosino Bio-Technology and Science (HKSE:08247), the current WACC % is 8.82% as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biosino Bio-Technology and Science (HKSE:08247) Overvalued in 2026?

Based on GuruFocus' analysis, Biosino Bio-Technology and Science stock appears to be overvalued. The current stock price of HK$3.17 is trading 619.3% above its estimated GF Value™ of HK$0.44. GuruFocus considers Biosino Bio-Technology and Science to be Significantly Overvalued.

Key valuation signals for HKSE:08247:

  • WACC %: 8.82% (81% above median its 10-year median of 4.87)
  • GF Value™: HK$0.44 vs. price of HK$3.17 (619.3% above fair value)
  • GF Score™: 37/100 with 6 warning signs
  • Industry Position: 1.4% below the Medical Diagnostics & Research median (#107 of 216)

No single metric tells the full story. See the HKSE:08247 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biosino Bio-Technology and Science Business Description

Address No. 27 Chaoqian Road, Science and Technology Industrial Park, Changping District, Beijing, CHN, 102200
Biosino Bio-Technology and Science Inc is engaged in the manufacture, sale, and distribution of IVD reagent products. The company operates in a single segment, the in-vitro diagnostic products segment, which manufactures, sells, and distributes a variety of mono/double diagnostic products. Geographically, it generates the majority of the revenue from Mainland China.
37GF Score

Get the complete analysis for HKSE:08247

WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.17
Price
HK$0.44
GF Value